March 13, 2013 -- Bracco Imaging has received approval from the U.K. Medicines and Health Care Products Regulatory Agency (MHRA) for expanded labeling of its MultiHance MRI agent, the company said.
The new labeling will allow MultiHance to be used for breast MRI -- for the detection of malignant lesions in patients where breast cancer is known or suspected on the basis of previous mammography or ultrasound results, according to the firm.
Bracco promotes MultiHance study results, March 11, 2013
Bracco acquires Swiss Medical Care, August 5, 2011
Bracco buys manufacturing facilities, May 23, 2011
Bracco revisits plans for U.S. launch of SonoVue, March 8, 2009
Bracco inks deal with Marillion, November 20, 2008